Climb Bio Reports Phase 2 Budoprutug Data, With 70% PLA2R Reduction
Climb Bio reported initial Phase 2 data showing budoprutug reduced PLA2R antibodies by a mean 70% at Week 12 in primary membranous nephropathy.
Climb Bio reported initial Phase 2 data showing budoprutug reduced PLA2R antibodies by a mean 70% at Week 12 in primary membranous nephropathy.Key Highlights:Original SEC Filing: Climb Bio, Inc. [ CLYM ] - 8-K - Oct. 26, 2026This is an AI-powered summary. It may contain inaccuracies.
Consider verif…